| 词条 | Esperion Therapeutics |
| 释义 |
|name = Esperion Therapeutics, Inc. |logo = |type = Public |traded_as = {{NASDAQ|ESPR}} Russell 2000 Component |foundation = {{Start date|2008}} |founder = {{unbulleted list|Dr. Roger Newton}} |industry = Pharmaceutical |location = Ann Arbor, Michigan |area_served = |key_people = Timothy M. Mayleben (president and CEO) |products = |revenue = |operating_income = |net_income = {{unbulleted list|{{decrease}}(US$26.1 million)loss (2013)|(US$11.7 million)loss (2012)}} |assets = {{unbulleted list|{{increase}}US$78.3 million (2013)|US$7.31 million (2012)}} |equity = |num_employees = |subsid = |footnotes = financial information{{rp|F-3,4}} |homepage = {{URL|www.esperion.com/|Esperion.com}} }} Esperion Therapeutics, Inc. is a public American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan. HistoryPfizer acquired the original Esperion in 2004 for {{currency|1.3 billion}} as a defensive move to prevent ETC-216 from falling into competitors' hands.[1]{{rp|165}} Two years later, in 2006, Pfizer decided to kill the Esperion organization and development of ETC-216. In May 2008, Dr. Roger Newton, Esperion's founder and chief scientific officer, raised sufficient capital to acquire rights to ETC-1002 and Esperion from Pfizer, thereby leading to a second independent period for the company.[1]{{rp|165}}[2][3] In June 2013, Esperion became a public company again through an initial public offering.[4] {{As of|2014|4}}, Esperion was traded on NASDAQ under the symbol "ESPR".[5]Product candidatesThe company's main product candidate, ETC-1002, is in phase II clinical development. {{cn|date=February 2019}} References1. ^1 {{cite book|title = Triumph of the Heart: The Story of Statins|last = Li|first = Jie Jack|year = 2009|publisher = Oxford University Press|isbn = 9780195323573}} 2. ^{{cite web| title=History| url=http://www.esperion.com/about-us/history.php| publisher=Esperion Therapeutics| archiveurl=https://web.archive.org/web/20120429013552/http://www.esperion.com/about-us/history.php| archivedate=April 29, 2012}} 3. ^{{cite journal|author=Catherine Shaffer|title=Pfizer jettisons Esperion|journal=Nat. Biotechnol.|volume=26|pages=724–725|year=2008|doi=10.1038/nbt0708-724|url=http://www.nature.com/nbt/journal/v26/n7/full/nbt0708-724.html|issue=7}}{{closed access}} 4. ^{{cite news|title=Burning Bright|author=Huggett, Brady|work=Nat. Biotechnol.|date=December 2013|pages=1068–71|volume=31|issue=12|url=http://www.nature.com/nbt/journal/v31/n12/full/nbt.2766.html}}{{open access}} 5. ^{{cite web|url=http://www.nasdaq.com/symbol/espr|title=ESPR stock quote|accessdate=April 22, 2014|publisher=NASDAQ}} }} Further reading
3 : Pharmaceutical companies of the United States|Companies listed on NASDAQ|Health care companies based in Michigan |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。